Page last updated: 2024-11-02

pioglitazone and Urinary Bladder Neoplasms

pioglitazone has been researched along with Urinary Bladder Neoplasms in 84 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.

Research Excerpts

ExcerptRelevanceReference
"To conduct a systematic review of all observational studies on the effect of pioglitazone on the risk of bladder cancer."9.01A systematic review of observational studies of the association between pioglitazone use and bladder cancer. ( Abrahamowicz, M; Azoulay, L; Platt, RW; Ripamonti, E; Suissa, S, 2019)
"We performed a meta-analysis of epidemiological studies evaluating exposure to pioglitazone and the risk for bladder cancer and compared these results to the drug's effects on cardiovascular disease (CVD) and non-alcoholic steatohepatitis (NASH)."8.98An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. ( Davidson, MB; Pan, D, 2018)
"Current evidence about the association between pioglitazone and bladder cancer risk remains conflict."8.98Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. ( Fu, S; Han, J; Shi, W; Song, Y; Tang, H; Wang, T; Zhai, S, 2018)
"Previous epidemiological studies reported inconsistent results regarding the association between pioglitazone use and the risk of bladder cancer (BC)."8.95Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis
. ( Li, Z; Shi, J; Sun, M; Wang, F; Wang, K, 2017)
"In preclinical studies, pioglitazone was associated with bladder cancer in male rats (but not in female rats, mice dogs or monkeys)."8.93Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence. ( Davidson, MB, 2016)
"Pioglitazone is widely used for glycemic control in patients with type 2 diabetes mellitus, but evidence regarding the association between pioglitazone and bladder cancer risk is confusing."8.90Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. ( He, S; Tang, YH; Wang, D; Yang, X; Zhang, Y; Zhao, G, 2014)
"Electronic databases were queried to identify controlled studies of pioglitazone that measured the risk of bladder cancer."8.89Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. ( Al-Mallah, MH; Ferwana, M; Firwana, B; Hasan, R; Kim, S; Montori, VM; Murad, MH, 2013)
"This article reviews human observations on pioglitazone and bladder cancer risk."8.88Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? ( Tseng, CH, 2012)
"Emerging studies suggest a possible increased risk of bladder cancer with pioglitazone therapy."8.88Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. ( Lu, Y; Shen, Z; Xu, C; Zhong, S; Zhu, Z, 2012)
" Food and Drug Administration and the European Medicines Agency have recently informed the public of a potential impact of pioglitazone (Actos) use on bladder cancer incidence."8.88Association between pioglitazone and urothelial bladder cancer. ( Barbalat, Y; Dombrovskiy, VY; Weiss, RE, 2012)
"National regulators in Australia and the United Kingdom issued safety advisories on the association between pioglitazone use and bladder cancer in July 2011."8.12Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study. ( Dormuth, CR; Kemp-Casey, A; Mintzes, B; Morrow, RL; Roughead, EE; Souverein, PC, 2022)
"Pioglitazone use in Asian-Indians is not associated with an increased bladder cancer risk."8.12Bladder cancer with pioglitazone: A case-control study. ( Bhadada, SK; Bhansali, A; Hiteshi, P; Khalkho, P; Kumar, N; Malhotra, B; Malhotra, S; Malik, R; Rajput, R; Rastogi, A; Shafiq, N, 2022)
"This paper thoroughly explores both in vitro and in vivo (animal models and humans) studies that investigated the possible association of pioglitazone with bladder cancer."8.12Pioglitazone, Bladder Cancer, and the Presumption of Innocence. ( Papaetis, GS, 2022)
"In 2011, France and Germany banned pioglitazone due to a concomitant risk for bladder cancer."7.91Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis. ( Bhushan, S; Prakash, J; Ray, RS; Singh, GN, 2019)
"The aim of the study was to empirically demonstrate the effect of varying study designs when evaluating the safety of pioglitazone in treating bladder cancer."7.91Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. ( Buse, JB; Garry, EM; Gokhale, M; Lund, JL; Nielsen, ME; Pate, V; Stürmer, T, 2019)
"To compare bladder cancer incidence between patients initiating pioglitazone treatment and patients initiating treatment with dipeptidyl-peptidase-4 inhibitors [DPP-4s] or sulfonylureas."7.88Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. ( Buse, JB; Garry, EM; Lund, JL; Pate, V; Stürmer, T, 2018)
"It has been debated for several years as to whether the antidiabetic drug pioglitazone increases the risk for bladder cancer."7.85Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes. ( Liu, Z; Qu, H; Ruan, X; Wang, Y; Yang, G; Zhang, R; Zheng, H; Zheng, Y, 2017)
"To determine whether pioglitazone compared with other antidiabetic drugs is associated with an increased risk of bladder cancer in people with type 2 diabetes."7.83Pioglitazone use and risk of bladder cancer: population based cohort study. ( Azoulay, L; Filion, KB; Platt, RW; Tuccori, M; Yin, H; Yu, OH, 2016)
" To evaluate the association between pioglitazone use and bladder cancer risk in patients with type 2 diabetes."7.83Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. ( Bahmanyar, S; Christopher, S; Dolin, P; Heintjes, EM; Hoti, F; Kool-Houweling, L; Korhonen, P; Linder, M; Majak, M; Strongman, H; Williams, R, 2016)
"The evidence on the association between pioglitazone use and bladder cancer is contradictory, with many studies subject to allocation bias."7.81Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. ( Badrick, E; Bell, S; Bowker, SL; Buchan, IE; Colhoun, HM; de Keyser, CE; Hartikainen, SA; Hofman, A; Johnson, JA; Keskimäki, I; Levin, D; MacDonald, TM; Marra, C; McKeigue, PM; Minhas-Sandhu, JK; Pukkala, E; Renehan, AG; Ruiter, R; Stricker, BH; Sund, R; Tuomilehto, J; Uitterlinden, AG; Wild, SH; Zafari, Z, 2015)
"Among 193,099 persons in the bladder cancer cohort, 34,181 (18%) received pioglitazone (median duration, 2."7.81Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. ( Bilker, W; Ehrlich, SF; Ferrara, A; Habel, LA; Hedderson, MM; Lewis, JD; Mamtani, R; Nessel, L; Peng, T; Quesenberry, CP; Strom, BL; Van Den Eeden, SK; Vaughn, DJ, 2015)
"The observed association between pioglitazone and bladder cancer could be causal or because of bias in the design of prior studies."7.80Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. ( Bilker, WB; Ferrara, A; Habel, L; Hedderson, M; Lewis, JD; Mamtani, R; Nessel, L; Peng, T; Quesenberry, C; Strom, BL; Vaughn, DJ, 2014)
"Although studies have shown an association between pioglitazone and bladder cancer, the associated factors have not been identified."7.80The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease. ( Hsiao, PJ; Lee, MY; Lin, KD; Shin, SJ; Yang, YH, 2014)
"This study aimed to identify the risk association between pioglitazone exposure and bladder cancer."7.80Pioglitazone use and the risk of bladder cancer. ( Ho, SC; Kuo, HW; Tiao, MM; Yang, CY, 2014)
"Prospective studies suggested an association between pioglitazone (Actos) use and the development of bladder cancer."7.80Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use. ( Gray, I; Hemal, A; Peyton, C; Romero, V; Terlecki, R, 2014)
"It has not yet been determined whether chronic exposure to relatively low doses of pioglitazone increases risk of bladder cancer."7.80Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. ( Chang, JS; Cho, JH; Jin, SM; Jung, CH; Jung, I; Kang, SM; Kim, JH; Lee, BW; Park, CY; Song, SO; Suh, S, 2014)
"Evidence has emerged that pioglitazone may increase the risk of bladder cancer, but the association has not been confirmed."7.79Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study. ( Gau, CS; Hsiao, FY; Hsieh, PH; Huang, WF; Tsai, YW, 2013)
"To examine whether exposure to pioglitazone use is associated with increased incidence of bladder cancer in patients with type 2 diabetes mellitus."7.79Pioglitazone and bladder cancer: a propensity score matched cohort study. ( MacDonald, TM; Mackenzie, IS; Wei, L, 2013)
"We retrospectively examined the frequency of bladder cancer in Japanese patients with type 2 diabetes in relation to use of pioglitazone."7.79Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. ( Fujikawa, J; Fujimoto, K; Hamamoto, Y; Honjo, S; Ikeda, H; Kawasaki, Y; Koshiyama, H; Matsuoka, A; Mori, K; Tatsuoka, H; Wada, Y, 2013)
"The association between pioglitazone and bladder cancer has not been investigated in Asians."7.78Pioglitazone and bladder cancer: a population-based study of Taiwanese. ( Tseng, CH, 2012)
"To determine if the use of pioglitazone is associated with an increased risk of incident bladder cancer in people with type 2 diabetes."7.78The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. ( Assayag, J; Azoulay, L; Filion, KB; Majdan, A; Pollak, MN; Suissa, S; Yin, H, 2012)
"Previous studies have suggested an increased risk of bladder cancer with pioglitazone exposure."7.78Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. ( Alla, F; Allemand, H; Fagot, JP; Neumann, A; Ricordeau, P; Weill, A, 2012)
"To analyze the association between pioglitazone use and bladder cancer through a spontaneous adverse event reporting system for medications."7.77Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. ( Marchesini, G; Motola, D; Piccinni, C; Poluzzi, E, 2011)
"Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy."7.77Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. ( Bilker, WB; Ferrara, A; Hedderson, M; Lewis, JD; Nessel, L; Peng, T; Quesenberry, CP; Selby, J; Strom, BL; Vaughn, DJ, 2011)
"Since then, the risk of bladder cancer associated with pioglitazone use has been a serious concern."6.49Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn? ( Faillie, JL; Hillaire-Buys, D; Montastruc, JL; Petit, P, 2013)
"Type 2 diabetes mellitus and bladder cancer were diagnosed using the International Statistical Classification of Diseases and Related Health Problems, 10th Revision code."5.43Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes. ( Choe, EY; Han, E; Jang, SY; Kang, ES; Kim, G; Lee, YH; Nam, CM, 2016)
"To conduct a systematic review of all observational studies on the effect of pioglitazone on the risk of bladder cancer."5.01A systematic review of observational studies of the association between pioglitazone use and bladder cancer. ( Abrahamowicz, M; Azoulay, L; Platt, RW; Ripamonti, E; Suissa, S, 2019)
"Current evidence about the association between pioglitazone and bladder cancer risk remains conflict."4.98Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. ( Fu, S; Han, J; Shi, W; Song, Y; Tang, H; Wang, T; Zhai, S, 2018)
"We performed a meta-analysis of epidemiological studies evaluating exposure to pioglitazone and the risk for bladder cancer and compared these results to the drug's effects on cardiovascular disease (CVD) and non-alcoholic steatohepatitis (NASH)."4.98An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. ( Davidson, MB; Pan, D, 2018)
"Previous epidemiological studies reported inconsistent results regarding the association between pioglitazone use and the risk of bladder cancer (BC)."4.95Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis
. ( Li, Z; Shi, J; Sun, M; Wang, F; Wang, K, 2017)
"In preclinical studies, pioglitazone was associated with bladder cancer in male rats (but not in female rats, mice dogs or monkeys)."4.93Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence. ( Davidson, MB, 2016)
"Pioglitazone is widely used for glycemic control in patients with type 2 diabetes mellitus, but evidence regarding the association between pioglitazone and bladder cancer risk is confusing."4.90Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. ( He, S; Tang, YH; Wang, D; Yang, X; Zhang, Y; Zhao, G, 2014)
" The use of pioglitazone has been associated with an increased risk of bladder cancer, edema, heart failure, weight gain, and distal bone fractures in postmenopausal women."4.89[Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus]. ( de Pablos-Velasco, PL; Valerón, PF, 2013)
"Electronic databases were queried to identify controlled studies of pioglitazone that measured the risk of bladder cancer."4.89Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. ( Al-Mallah, MH; Ferwana, M; Firwana, B; Hasan, R; Kim, S; Montori, VM; Murad, MH, 2013)
"This article reviews human observations on pioglitazone and bladder cancer risk."4.88Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? ( Tseng, CH, 2012)
" Food and Drug Administration and the European Medicines Agency have recently informed the public of a potential impact of pioglitazone (Actos) use on bladder cancer incidence."4.88Association between pioglitazone and urothelial bladder cancer. ( Barbalat, Y; Dombrovskiy, VY; Weiss, RE, 2012)
"Emerging studies suggest a possible increased risk of bladder cancer with pioglitazone therapy."4.88Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. ( Lu, Y; Shen, Z; Xu, C; Zhong, S; Zhu, Z, 2012)
"The limited evidence available supports the hypothesis that thiazolidinediones, particularly pioglitazone, are associated with an increased risk of bladder cancer among adults with type 2 diabetes."4.88Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. ( Bowker, SL; Colmers, IN; Johnson, JA; Majumdar, SR, 2012)
"This paper thoroughly explores both in vitro and in vivo (animal models and humans) studies that investigated the possible association of pioglitazone with bladder cancer."4.12Pioglitazone, Bladder Cancer, and the Presumption of Innocence. ( Papaetis, GS, 2022)
"National regulators in Australia and the United Kingdom issued safety advisories on the association between pioglitazone use and bladder cancer in July 2011."4.12Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study. ( Dormuth, CR; Kemp-Casey, A; Mintzes, B; Morrow, RL; Roughead, EE; Souverein, PC, 2022)
"Pioglitazone use in Asian-Indians is not associated with an increased bladder cancer risk."4.12Bladder cancer with pioglitazone: A case-control study. ( Bhadada, SK; Bhansali, A; Hiteshi, P; Khalkho, P; Kumar, N; Malhotra, B; Malhotra, S; Malik, R; Rajput, R; Rastogi, A; Shafiq, N, 2022)
"The aim of the study was to empirically demonstrate the effect of varying study designs when evaluating the safety of pioglitazone in treating bladder cancer."3.91Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. ( Buse, JB; Garry, EM; Gokhale, M; Lund, JL; Nielsen, ME; Pate, V; Stürmer, T, 2019)
"In 2011, France and Germany banned pioglitazone due to a concomitant risk for bladder cancer."3.91Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis. ( Bhushan, S; Prakash, J; Ray, RS; Singh, GN, 2019)
"To compare bladder cancer incidence between patients initiating pioglitazone treatment and patients initiating treatment with dipeptidyl-peptidase-4 inhibitors [DPP-4s] or sulfonylureas."3.88Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. ( Buse, JB; Garry, EM; Lund, JL; Pate, V; Stürmer, T, 2018)
"Pioglitazone was suspended for manufacture and sale by the Indian drug regulator in June 2013 due to its association with urinary bladder carcinoma, which was revoked within a short period (July 2013)."3.85Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study. ( Adhikari, A; Ambwani, S; Badyal, DK; Bairy, KL; Bhandare, B; Chakrabarti, A; Chandrashekar, K; Das, N; Dhamija, P; Dhasmana, DC; Goyal, A; Goyal, C; Gupta, YK; Jayanthi, CR; Kakkar, AK; Kaur, I; Kaushal, S; Kumar, R; Mazumdar, G; Munshi, R; Rehman, SU; Sarangi, SC; Sehgal, VK; Singh, H; Singh, J; Stephy, DJ; Thangaraju, P, 2017)
"It has been debated for several years as to whether the antidiabetic drug pioglitazone increases the risk for bladder cancer."3.85Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes. ( Liu, Z; Qu, H; Ruan, X; Wang, Y; Yang, G; Zhang, R; Zheng, H; Zheng, Y, 2017)
" To evaluate the association between pioglitazone use and bladder cancer risk in patients with type 2 diabetes."3.83Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. ( Bahmanyar, S; Christopher, S; Dolin, P; Heintjes, EM; Hoti, F; Kool-Houweling, L; Korhonen, P; Linder, M; Majak, M; Strongman, H; Williams, R, 2016)
"To determine whether pioglitazone compared with other antidiabetic drugs is associated with an increased risk of bladder cancer in people with type 2 diabetes."3.83Pioglitazone use and risk of bladder cancer: population based cohort study. ( Azoulay, L; Filion, KB; Platt, RW; Tuccori, M; Yin, H; Yu, OH, 2016)
"The evidence on the association between pioglitazone use and bladder cancer is contradictory, with many studies subject to allocation bias."3.81Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. ( Badrick, E; Bell, S; Bowker, SL; Buchan, IE; Colhoun, HM; de Keyser, CE; Hartikainen, SA; Hofman, A; Johnson, JA; Keskimäki, I; Levin, D; MacDonald, TM; Marra, C; McKeigue, PM; Minhas-Sandhu, JK; Pukkala, E; Renehan, AG; Ruiter, R; Stricker, BH; Sund, R; Tuomilehto, J; Uitterlinden, AG; Wild, SH; Zafari, Z, 2015)
"Among 193,099 persons in the bladder cancer cohort, 34,181 (18%) received pioglitazone (median duration, 2."3.81Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. ( Bilker, W; Ehrlich, SF; Ferrara, A; Habel, LA; Hedderson, MM; Lewis, JD; Mamtani, R; Nessel, L; Peng, T; Quesenberry, CP; Strom, BL; Van Den Eeden, SK; Vaughn, DJ, 2015)
"It has not yet been determined whether chronic exposure to relatively low doses of pioglitazone increases risk of bladder cancer."3.80Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. ( Chang, JS; Cho, JH; Jin, SM; Jung, CH; Jung, I; Kang, SM; Kim, JH; Lee, BW; Park, CY; Song, SO; Suh, S, 2014)
"This study aimed to identify the risk association between pioglitazone exposure and bladder cancer."3.80Pioglitazone use and the risk of bladder cancer. ( Ho, SC; Kuo, HW; Tiao, MM; Yang, CY, 2014)
"Although studies have shown an association between pioglitazone and bladder cancer, the associated factors have not been identified."3.80The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease. ( Hsiao, PJ; Lee, MY; Lin, KD; Shin, SJ; Yang, YH, 2014)
"The observed association between pioglitazone and bladder cancer could be causal or because of bias in the design of prior studies."3.80Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. ( Bilker, WB; Ferrara, A; Habel, L; Hedderson, M; Lewis, JD; Mamtani, R; Nessel, L; Peng, T; Quesenberry, C; Strom, BL; Vaughn, DJ, 2014)
"Prospective studies suggested an association between pioglitazone (Actos) use and the development of bladder cancer."3.80Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use. ( Gray, I; Hemal, A; Peyton, C; Romero, V; Terlecki, R, 2014)
"Compared with insulin, pioglitazone was associated with a significant reduction in the risk of MI and stroke requiring hospitalization, and a significant reduction in the risk of other selected cancers."3.79Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. ( Bron, M; Fusco, G; Joseph, G; Liang, H; Manne, S; Perez, A; Vallarino, C; Yu, S, 2013)
"To examine whether exposure to pioglitazone use is associated with increased incidence of bladder cancer in patients with type 2 diabetes mellitus."3.79Pioglitazone and bladder cancer: a propensity score matched cohort study. ( MacDonald, TM; Mackenzie, IS; Wei, L, 2013)
"Evidence has emerged that pioglitazone may increase the risk of bladder cancer, but the association has not been confirmed."3.79Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study. ( Gau, CS; Hsiao, FY; Hsieh, PH; Huang, WF; Tsai, YW, 2013)
"We retrospectively examined the frequency of bladder cancer in Japanese patients with type 2 diabetes in relation to use of pioglitazone."3.79Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. ( Fujikawa, J; Fujimoto, K; Hamamoto, Y; Honjo, S; Ikeda, H; Kawasaki, Y; Koshiyama, H; Matsuoka, A; Mori, K; Tatsuoka, H; Wada, Y, 2013)
"The use of pioglitazone, a thiazolidinedione (TZD), may increase the risk of bladder cancer in patients with type 2 diabetes."3.78Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. ( Bilker, WB; Glanz, K; Haynes, K; Lewis, JD; Mamtani, R; Strom, BL; Vaughn, DJ, 2012)
"The association between pioglitazone and bladder cancer has not been investigated in Asians."3.78Pioglitazone and bladder cancer: a population-based study of Taiwanese. ( Tseng, CH, 2012)
"Previous studies have suggested an increased risk of bladder cancer with pioglitazone exposure."3.78Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. ( Alla, F; Allemand, H; Fagot, JP; Neumann, A; Ricordeau, P; Weill, A, 2012)
"To determine if the use of pioglitazone is associated with an increased risk of incident bladder cancer in people with type 2 diabetes."3.78The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. ( Assayag, J; Azoulay, L; Filion, KB; Majdan, A; Pollak, MN; Suissa, S; Yin, H, 2012)
"Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy."3.77Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. ( Bilker, WB; Ferrara, A; Hedderson, M; Lewis, JD; Nessel, L; Peng, T; Quesenberry, CP; Selby, J; Strom, BL; Vaughn, DJ, 2011)
"To analyze the association between pioglitazone use and bladder cancer through a spontaneous adverse event reporting system for medications."3.77Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. ( Marchesini, G; Motola, D; Piccinni, C; Poluzzi, E, 2011)
"Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow-up; however, these imbalances should be interpreted with caution because of the limitations of the observational study design."2.82Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. ( Erdmann, E; Harding, S; Lam, H; Perez, A, 2016)
"The double-blind period bladder cancer imbalance did not persist in follow-up."2.79Observational follow-up of the PROactive study: a 6-year update. ( Erdmann, E; Perez, A; Song, E; Spanheimer, R; van Troostenburg de Bruyn, AR, 2014)
"Since then, the risk of bladder cancer associated with pioglitazone use has been a serious concern."2.49Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn? ( Faillie, JL; Hillaire-Buys, D; Montastruc, JL; Petit, P, 2013)
"Type 2 diabetes mellitus and bladder cancer were diagnosed using the International Statistical Classification of Diseases and Related Health Problems, 10th Revision code."1.43Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes. ( Choe, EY; Han, E; Jang, SY; Kang, ES; Kim, G; Lee, YH; Nam, CM, 2016)

Research

Studies (84)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (3.57)29.6817
2010's76 (90.48)24.3611
2020's5 (5.95)2.80

Authors

AuthorsStudies
Papaetis, GS1
Kemp-Casey, A1
Mintzes, B1
Morrow, RL1
Dormuth, CR1
Souverein, PC1
Roughead, EE1
Malhotra, B1
Hiteshi, P1
Khalkho, P1
Malik, R1
Bhadada, SK1
Bhansali, A1
Shafiq, N1
Malhotra, S1
Kumar, N1
Rajput, R1
Rastogi, A1
Bhushan, S1
Ray, RS1
Prakash, J1
Singh, GN1
Jeong, HE1
Cho, SI1
Oh, IS1
Baek, YH1
Shin, JY1
Ripamonti, E2
Azoulay, L4
Abrahamowicz, M2
Platt, RW3
Suissa, S3
Atlı Şekeroğlu, Z1
Şekeroğlu, V1
Kontaş Yedier, S1
İlkun, E1
Liou, LS1
Aschenbrenner, DS1
Garry, EM2
Buse, JB2
Lund, JL2
Pate, V2
Stürmer, T2
Li, R1
Metcalfe, MJ1
Ferguson, JE1
Mokkapati, S1
Nogueras González, GM1
Dinney, CP1
Navai, N1
McConkey, DJ1
Sahai, SK1
Kamat, AM1
Davidson, MB2
Pan, D1
Qu, H1
Zheng, Y1
Wang, Y1
Zhang, R1
Ruan, X1
Yang, G1
Liu, Z1
Zheng, H1
Goyal, A1
Singh, H1
Sehgal, VK1
Jayanthi, CR1
Munshi, R1
Bairy, KL1
Kumar, R1
Kaushal, S1
Kakkar, AK1
Ambwani, S1
Goyal, C1
Mazumdar, G1
Adhikari, A1
Das, N1
Stephy, DJ1
Thangaraju, P1
Dhasmana, DC1
Rehman, SU1
Chakrabarti, A1
Bhandare, B1
Badyal, DK1
Kaur, I1
Chandrashekar, K1
Singh, J1
Dhamija, P1
Sarangi, SC1
Gupta, YK1
Tang, H1
Shi, W1
Fu, S1
Wang, T1
Zhai, S1
Song, Y1
Han, J1
Griebling, TL1
Gokhale, M1
Nielsen, ME1
Ryder, REJ1
DeFronzo, RA1
Gomella, LG1
de Vries, F1
Zeegers, M1
Goossens, ME1
Unnikrishnan, R2
Sundramoorthy, C1
Deshpande, N1
Sarvothaman, R1
Sahay, RK1
Mehtalia, S1
Venkatraman, JV1
Mohan, V2
Hsiao, FY1
Hsieh, PH1
Huang, WF1
Tsai, YW1
Gau, CS1
Erdmann, E2
Song, E1
Spanheimer, R1
van Troostenburg de Bruyn, AR1
Perez, A3
Faillie, JL4
Petit, P2
Montastruc, JL2
Hillaire-Buys, D4
Vallarino, C1
Fusco, G1
Liang, H1
Bron, M1
Manne, S1
Joseph, G1
Yu, S1
He, S1
Tang, YH1
Zhao, G1
Yang, X1
Wang, D1
Zhang, Y1
Lee, MY1
Hsiao, PJ1
Yang, YH1
Lin, KD1
Shin, SJ1
Valerón, PF1
de Pablos-Velasco, PL1
Kuo, HW1
Tiao, MM1
Ho, SC1
Yang, CY1
Romero, V1
Peyton, C1
Gray, I1
Hemal, A1
Terlecki, R1
Jin, SM1
Song, SO1
Jung, CH1
Chang, JS1
Suh, S1
Kang, SM1
Jung, I1
Park, CY1
Kim, JH1
Cho, JH1
Lee, BW1
Tseng, CH3
Lewis, JD4
Habel, L1
Quesenberry, C1
Mamtani, R3
Peng, T3
Bilker, WB3
Hedderson, M2
Nessel, L3
Vaughn, DJ4
Strom, BL4
Ferrara, A3
Mello, MM1
Cohen, IG1
Kernan, WN1
Viscoli, CM1
Varughese, MC1
Lee, EJ1
Marcy, TR1
Ryder, RE1
Levin, D1
Bell, S1
Sund, R1
Hartikainen, SA1
Tuomilehto, J1
Pukkala, E1
Keskimäki, I1
Badrick, E1
Renehan, AG1
Buchan, IE1
Bowker, SL2
Minhas-Sandhu, JK1
Zafari, Z1
Marra, C1
Johnson, JA3
Stricker, BH1
Uitterlinden, AG1
Hofman, A1
Ruiter, R1
de Keyser, CE1
MacDonald, TM2
Wild, SH1
McKeigue, PM1
Colhoun, HM1
Habel, LA1
Quesenberry, CP2
Hedderson, MM1
Ehrlich, SF1
Bilker, W1
Van Den Eeden, SK1
Warren, H1
Raison, N1
Dasgupta, P1
Harding, S1
Lam, H1
Han, E1
Jang, SY1
Kim, G1
Lee, YH1
Choe, EY1
Nam, CM1
Kang, ES1
Chedgy, EC1
Black, PC1
Tuccori, M1
Filion, KB2
Yin, H2
Yu, OH1
Kado, T1
Usui, I1
Tobe, K1
Winnenburg, R1
Shah, NH1
Korhonen, P1
Heintjes, EM1
Williams, R1
Hoti, F1
Christopher, S1
Majak, M1
Kool-Houweling, L1
Strongman, H1
Linder, M1
Dolin, P1
Bahmanyar, S1
Li, Z1
Sun, M1
Wang, F1
Shi, J1
Wang, K1
Usman, MS1
Rizwan, T1
Ahmed, F1
Hampp, C1
Pippins, J1
Sato, K1
Awasaki, Y1
Kandori, H1
Tanakamaru, ZY1
Nagai, H1
Baron, D1
Yamamoto, M1
Selby, J1
Piccinni, C1
Motola, D1
Marchesini, G1
Poluzzi, E1
Stephenson, J1
Goldstein, MR2
Mascitelli, L1
Nicolau Ramis, J1
Masmiquel Comas, L1
Neumann, A1
Weill, A1
Ricordeau, P1
Fagot, JP1
Alla, F1
Allemand, H1
Wei, L1
Mackenzie, IS1
Barbalat, Y1
Dombrovskiy, VY1
Weiss, RE1
Assayag, J1
Majdan, A1
Pollak, MN1
Zhu, Z1
Shen, Z1
Lu, Y1
Zhong, S1
Xu, C1
Bedi, S1
Sahay, BK1
Joshpi, S1
Misra, A1
Panikar, V1
Kalra, S1
Voelker, R1
Colmers, IN2
Majumdar, SR1
Kermode-Scott, B1
Haynes, K1
Glanz, K1
Kawamori, R1
Fujimoto, K1
Hamamoto, Y1
Honjo, S1
Kawasaki, Y1
Mori, K1
Tatsuoka, H1
Matsuoka, A1
Wada, Y1
Ikeda, H1
Fujikawa, J1
Koshiyama, H1
Cagiltay, E1
Tuncel, T1
Yönem, A1
Ozdemir, G1
Noon, AP1
Catto, JW1
Ferwana, M1
Firwana, B1
Hasan, R1
Al-Mallah, MH1
Kim, S1
Montori, VM1
Murad, MH1
Achanzar, WE1
Moyer, CF1
Marthaler, LT1
Gullo, R1
Chen, SJ1
French, MH1
Watson, LM1
Rhodes, JW1
Kozlosky, JC1
White, MR1
Foster, WR1
Burgun, JJ1
Car, BD1
Cosma, GN1
Dominick, MA1
Nakashiro, KI1
Hayashi, Y1
Kita, A1
Tamatani, T1
Chlenski, A1
Usuda, N1
Hattori, K1
Reddy, JK1
Oyasu, R1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Participation Trends in Bladder Cancer Clinical Trials - Exploring Engagement Dynamics Among Individuals Impacted by Bladder Cancer[NCT06009510]500 participants (Anticipated)Observational2024-09-30Not yet recruiting
Cohort Study of Pioglitazone and Bladder Cancer in Patients With Diabetes[NCT01637935]193,099 participants (Actual)Observational2004-07-31Completed
An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications.[NCT02678676]3,599 participants (Actual)Observational [Patient Registry]2004-11-30Completed
The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial[NCT02491333]Phase 3342 participants (Actual)Interventional2015-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Incident Diagnosis of Bladder Cancer (10-year Analysis)

Incident bladder cancers were identified from January 1, 1997 to December 31, 2012. (NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012

Interventionevents per 100,000 person years (Number)
Pioglitazone Exposed Group89.8
Pioglitazone Unexposed Group75.9

Incident Diagnosis of Bladder Cancer by Cumulative Dose of Pioglitazone (10 Year Analysis)

(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012

,
Interventionevents per 100,000 person years (Number)
1 - 14000 mg14001 - 40000 mg>40000 mg
Pioglitazone Exposed Group69.196.9101.4
Pioglitazone Unexposed GroupNANANA

Incident Diagnosis of Bladder Cancer by Duration of Pioglitazone Therapy (10 Year Analysis)

(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012

,
Interventionevents per 100,000 person years (Number)
Less than 1.5 years1.5 - 4.0 yearsMore than 4 years
Pioglitazone Exposed Group67.588.4113.7
Pioglitazone Unexposed GroupNANANA

Incident Diagnosis of Bladder Cancer by Time Since Starting Pioglitazone (10 Year Analysis)

(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012

,
Interventionevents per 100,000 person years (Number)
Less than 4.5 years4.5 -8.5 yearsMore than 8.0 years
Pioglitazone Exposed Group68.2111.6125.8
Pioglitazone Unexposed GroupNANANA

Stage of Bladder Cancer (10 Year Analysis)

(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012

,
Interventionpercentage of participants (Number)
PUNLMPIn situLocalRegionalDistantUndetermined
Pioglitazone Exposed Group15040423
Pioglitazone Unexposed Group14938633

Incidences With Malignancies

Percentage of participants with incidences of at least 1 malignancy was reported. All malignancies included adrenal, biliary, bladder, brain, breast, cervix, colon/rectal, gastric, hematological, hepatic, lung, mesothelioma, metastases, oesophageal, oropharyngeal, ovarian/uterine, pancreas, prostate, renal, skin and others. (NCT02678676)
Timeframe: Up to Year 10

Interventionpercentage of participants (Number)
Pioglitazone12.9
Placebo13.2

Percentage of Participants With First Occurrence of Macro-vascular Event or Death

The composite macro-vascular event or death included all-cause mortality, non-fatal myocardial infarction, cardiac intervention, stroke, major leg amputation (above the ankle), bypass surgery or revascularization in the leg. The percentage of participants in the observational study population having first occurrence of macro-vascular event or death during the 10-year observational study period was analyzed. The data were analyzed using the Cox regression with respect to time to the first occurrence of macro-vascular event or death. (NCT02678676)
Timeframe: Up to Year 10

Interventionpercentage of participants (Number)
Pioglitazone58
Placebo60.3

Reviews

19 reviews available for pioglitazone and Urinary Bladder Neoplasms

ArticleYear
An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis.
    Diabetes research and clinical practice, 2018, Volume: 135

    Topics: Cardiovascular Diseases; Cohort Studies; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Dise

2018
Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.
    Cancer medicine, 2018, Volume: 7, Issue:4

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Odds Ratio; Pioglitazone; Randomized Control

2018
A systematic review of observational studies of the association between pioglitazone use and bladder cancer.
    Diabetic medicine : a journal of the British Diabetic Association, 2019, Volume: 36, Issue:1

    Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Incidence;

2019
Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?
    Drug safety, 2013, Volume: 36, Issue:9

    Topics: Animals; Europe; Humans; Pharmacoepidemiology; Pioglitazone; Risk Assessment; Thiazolidinediones; Un

2013
Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:3

    Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Pioglitazone; Risk

2014
[Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
    Medicina clinica, 2013, Volume: 141 Suppl 2

    Topics: Contraindications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Comb

2013
A review on thiazolidinediones and bladder cancer in human studies.
    Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews, 2014, Volume: 32, Issue:1

    Topics: Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazolidinediones

2014
Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit.
    Diabetic medicine : a journal of the British Diabetic Association, 2015, Volume: 32, Issue:3

    Topics: Animals; Cardiovascular System; Diabetes Mellitus, Type 2; Disease Models, Animal; Endpoint Determin

2015
Examples of how the pharmaceutical industries distort the evidence of drug safety: the case of pioglitazone and the bladder cancer issue.
    Pharmacoepidemiology and drug safety, 2016, Volume: 25, Issue:2

    Topics: Animals; Drug Industry; Humans; Hypoglycemic Agents; Pharmacoepidemiology; Pioglitazone; Scientific

2016
Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence.
    Journal of diabetes and its complications, 2016, Volume: 30, Issue:6

    Topics: Diabetes Mellitus, Type 2; Drug Industry; Female; Humans; Hypoglycemic Agents; Male; Pioglitazone; R

2016
Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis
.
    International journal of clinical pharmacology and therapeutics, 2017, Volume: 55, Issue:3

    Topics: Diabetes Mellitus; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Linear Models; Mul

2017
Pioglitazone and bladder cancer: FDA's assessment.
    Pharmacoepidemiology and drug safety, 2017, Volume: 26, Issue:2

    Topics: Humans; Hypoglycemic Agents; Pioglitazone; Randomized Controlled Trials as Topic; United States; Uni

2017
Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2012, Volume: 111, Issue:3

    Topics: Bias; Comorbidity; Data Interpretation, Statistical; Diabetes Complications; Epidemiologic Research

2012
Association between pioglitazone and urothelial bladder cancer.
    Urology, 2012, Volume: 80, Issue:1

    Topics: Clinical Trials as Topic; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidinediones; Urinary Bla

2012
Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
    Diabetes research and clinical practice, 2012, Volume: 98, Issue:1

    Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Pio

2012
Pioglitazone--where do we stand in India?
    The Journal of the Association of Physicians of India, 2012, Volume: 60

    Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Rela

2012
Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2012, Sep-04, Volume: 184, Issue:12

    Topics: Adult; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Humans; Incidence; Pioglitazone; Rand

2012
Bladder cancer in 2012: Challenging current paradigms.
    Nature reviews. Urology, 2013, Volume: 10, Issue:2

    Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Cystectomy; Humans; Pioglitazone; Rand

2013
Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
    Diabetic medicine : a journal of the British Diabetic Association, 2013, Volume: 30, Issue:9

    Topics: Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglyce

2013

Trials

2 trials available for pioglitazone and Urinary Bladder Neoplasms

ArticleYear
Observational follow-up of the PROactive study: a 6-year update.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:1

    Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studi

2014
Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:3

    Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studi

2016

Other Studies

63 other studies available for pioglitazone and Urinary Bladder Neoplasms

ArticleYear
Pioglitazone, Bladder Cancer, and the Presumption of Innocence.
    Current drug safety, 2022, Volume: 17, Issue:4

    Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; Thiazolidine

2022
Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study.
    Pharmacoepidemiology and drug safety, 2022, Volume: 31, Issue:10

    Topics: Aged; Australia; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Interrupted Time Se

2022
Bladder cancer with pioglitazone: A case-control study.
    Diabetes & metabolic syndrome, 2022, Volume: 16, Issue:11

    Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Female; Hematuria; Humans; Hypoglycemic Agents; Mal

2022
Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
    Clinical therapeutics, 2019, Volume: 41, Issue:11

    Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Female; Global Health; Humans; Hypoglyce

2019
Prescribing trend of pioglitazone after safety warning release in Korea.
    The American journal of managed care, 2019, 11-01, Volume: 25, Issue:11

    Topics: Diabetes Mellitus, Type 2; Drug Utilization; Female; Humans; Hypoglycemic Agents; Interrupted Time S

2019
Pioglitazone and bladder cancer: improving research methods.
    Diabetic medicine : a journal of the British Diabetic Association, 2020, Volume: 37, Issue:5

    Topics: Humans; Hypoglycemic Agents; Pioglitazone; Research Design; Thiazolidinediones; Urinary Bladder Neop

2020
Increased DNA strand breaks and neoplastic transformation in human bladder cells treated with pioglitazone.
    Environmental and molecular mutagenesis, 2021, Volume: 62, Issue:2

    Topics: Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Diabetes Mellitus, Type 2; DNA; DN

2021
Updated Review Confirms Potential Risk of Bladder Cancer with Pioglitazone.
    The American journal of nursing, 2017, Volume: 117, Issue:4

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk; Thiazolidinediones; Urin

2017
Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:1

    Topics: Aged; Aged, 80 and over; Aging; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV I

2018
Effects of thiazolidinedione in patients with active bladder cancer.
    BJU international, 2018, Volume: 121, Issue:2

    Topics: Aged; Carcinoma, Transitional Cell; Cystectomy; Diabetes Mellitus; Disease-Free Survival; Female; Hu

2018
Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes.
    Scientific reports, 2017, Nov-17, Volume: 7, Issue:1

    Topics: Diabetes Mellitus, Type 2; Humans; Observational Studies as Topic; Pioglitazone; Randomized Controll

2017
Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study.
    The Indian journal of medical research, 2017, Volume: 146, Issue:4

    Topics: Adult; Aged; Carcinoma; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; India; Male;

2017
Re: Comparative Safety of Pioglitazone versus Clinically Meaningful Treatment Alternatives Concerning the Risk of Bladder Cancer in Older US Adults with Type 2 Diabetes.
    The Journal of urology, 2019, Volume: 201, Issue:6

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Urin

2019
Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:9

    Topics: Aged; Aged, 80 and over; Comparative Effectiveness Research; Diabetes Complications; Diabetes Mellit

2019
Pioglitazone: inexpensive; very effective at reducing HbA
    Diabetic medicine : a journal of the British Diabetic Association, 2019, Volume: 36, Issue:9

    Topics: Humans; Hypoglycemic Agents; Pioglitazone; Risk; Thiazolidinediones; Urinary Bladder Neoplasms

2019
Actos, slings, finasteride, and the vaccine compensation solution.
    The Canadian journal of urology, 2013, Volume: 20, Issue:2

    Topics: Finasteride; Humans; Liability, Legal; Male; Patient Rights; Pioglitazone; Prostatic Neoplasms; Risk

2013
Pioglitazone and bladder cancer: two studies, same database, two answers.
    British journal of clinical pharmacology, 2013, Volume: 76, Issue:3

    Topics: Data Interpretation, Statistical; Databases, Factual; Epidemiologic Research Design; Humans; Hypogly

2013
Eight cases of bladder cancer in pioglitazone users from India.
    The Journal of the Association of Physicians of India, 2012, Volume: 60

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; India; Male; Middle Age

2012
Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
    Drug safety, 2013, Volume: 36, Issue:8

    Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidenc

2013
Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.
    Clinical drug investigation, 2013, Volume: 33, Issue:9

    Topics: Aged; Aged, 80 and over; Cohort Studies; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Insul

2013
The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Adult; Aged; Asian People; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycem

2014
Pioglitazone use and the risk of bladder cancer.
    The Kaohsiung journal of medical sciences, 2014, Volume: 30, Issue:2

    Topics: Aged; Aged, 80 and over; Case-Control Studies; Female; Humans; Hypoglycemic Agents; Logistic Models;

2014
Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use.
    BMC urology, 2014, Jan-25, Volume: 14

    Topics: Aged; Cystectomy; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Pioglitazone; Retros

2014
Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study.
    Journal of Korean medical science, 2014, Volume: 29, Issue:2

    Topics: Aged; Asian People; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans;

2014
Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
    Pharmacoepidemiology and drug safety, 2014, Volume: 23, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; California; Cohort Studies; Confounding Factors, Epidemiologic; Diab

2014
Clinical trials and the right to remain silent.
    JAMA internal medicine, 2014, Volume: 174, Issue:9

    Topics: Access to Information; Biomedical Research; Humans; Hypoglycemic Agents; Pioglitazone; Randomized Co

2014
Litigation seeking access to data from ongoing clinical trials: a threat to clinical research.
    JAMA internal medicine, 2014, Volume: 174, Issue:9

    Topics: Access to Information; Biomedical Research; Connecticut; Diabetes Mellitus, Type 2; Humans; Hypoglyc

2014
The impact of pioglitazone on bladder cancer and cardiovascular events.
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2014, Volume: 29, Issue:8

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Risk; U

2014
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
    Diabetologia, 2015, Volume: 58, Issue:3

    Topics: Aged; British Columbia; Diabetes Mellitus, Type 2; Female; Finland; Humans; Hypoglycemic Agents; Inc

2015
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
    JAMA, 2015, Jul-21, Volume: 314, Issue:3

    Topics: Adult; Aged, 80 and over; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Female; H

2015
Pioglitazone and bladder cancer.
    BJU international, 2016, Volume: 118, Issue:1

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidinediones; Urinary Bl

2016
Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.
    Medicine, 2016, Volume: 95, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyp

2016
Pioglitazone: No Longer a Worry for Bladder Cancer?
    Urology, 2016, Volume: 91

    Topics: Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidinediones; Urinary Bladder Neoplasms

2016
Pioglitazone use and risk of bladder cancer: population based cohort study.
    BMJ (Clinical research ed.), 2016, Mar-30, Volume: 352

    Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; General Practice; Humans; Hypoglycemic Agents; Ma

2016
[Pioglitazone and the risk of bladder cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2016, Volume: 74 Suppl 2

    Topics: Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidinedi

2016
Generalized enrichment analysis improves the detection of adverse drug events from the biomedical literature.
    BMC bioinformatics, 2016, Jun-23, Volume: 17

    Topics: Animals; Computational Biology; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemi

2016
Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.
    BMJ (Clinical research ed.), 2016, Aug-16, Volume: 354

    Topics: Aged; Datasets as Topic; Diabetes Mellitus, Type 2; Female; Finland; Humans; Hypoglycemic Agents; Ma

2016
A word of caution regarding pioglitazone.
    JPMA. The Journal of the Pakistan Medical Association, 2017, Volume: 67, Issue:1

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pakistan; Patient Safety; Pioglitazone; Urin

2017
Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats.
    Toxicology and applied pharmacology, 2011, Mar-15, Volume: 251, Issue:3

    Topics: Ammonium Chloride; Animals; Citrates; Diet; Hydrogen-Ion Concentration; Hypoglycemic Agents; Lasers;

2011
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.
    Diabetes care, 2011, Volume: 34, Issue:4

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Longitudinal Studies; M

2011
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.
    Diabetes care, 2011, Volume: 34, Issue:6

    Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Female; Humans; Hypoglycemic Agent

2011
Diabetes drug may be associated with increase in risk of bladder cancer.
    JAMA, 2011, Jul-13, Volume: 306, Issue:2

    Topics: Contraindications; Diabetes Mellitus; Drug Labeling; Humans; Hypoglycemic Agents; Pioglitazone; Risk

2011
Pioglitazone for diabetes prevention.
    The New England journal of medicine, 2011, 07-14, Volume: 365, Issue:2

    Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolid

2011
[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2012, Volume: 59, Issue:1

    Topics: Animals; Breast Neoplasms; Calcitonin; Carcinoma, Medullary; Clinical Trials as Topic; Comorbidity;

2012
Pioglitazone and bladder cancer: a population-based study of Taiwanese.
    Diabetes care, 2012, Volume: 35, Issue:2

    Topics: Asian People; Female; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazolidinediones; Urinary B

2012
Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
    Diabetologia, 2012, Volume: 55, Issue:7

    Topics: Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Follow

2012
Pioglitazone and bladder cancer: a propensity score matched cohort study.
    British journal of clinical pharmacology, 2013, Volume: 75, Issue:1

    Topics: Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; M

2013
Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!
    European journal of clinical pharmacology, 2012, Volume: 68, Issue:12

    Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Oxazoles; Pioglitazone; PPAR alpha;

2012
Pioglitazone and the risk of bladder cancer.
    BMJ (Clinical research ed.), 2012, May-30, Volume: 344

    Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazolidinedion

2012
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.
    BMJ (Clinical research ed.), 2012, May-30, Volume: 344

    Topics: Administration, Oral; Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Dose-Response Re

2012
Pioglitazone and bladder cancer: the pros and cons.
    The Journal of the Association of Physicians of India, 2012, Volume: 60

    Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Rela

2012
The cage in search of a bird.
    The Journal of the Association of Physicians of India, 2012, Volume: 60

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Piogl

2012
Diabetes drug is linked with bladder cancer risk.
    JAMA, 2012, Jun-27, Volume: 307, Issue:24

    Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Labeling; Humans; Hypoglycemic Agents; M

2012
Meta-analysis confirms raised risk of bladder cancer from pioglitazone.
    BMJ (Clinical research ed.), 2012, Jul-04, Volume: 345

    Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic

2012
Pioglitazone: European approval maintained despite the acknowledged risks.
    Prescrire international, 2012, Volume: 21, Issue:129

    Topics: Diabetes Mellitus, Type 2; France; Humans; Hypoglycemic Agents; Pioglitazone; Risk; Thiazolidinedion

2012
Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
    Journal of the National Cancer Institute, 2012, Sep-19, Volume: 104, Issue:18

    Topics: Aged; Cohort Studies; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Dose-Response R

2012
Balancing the risks and benefits for pioglitazone in type 2 diabetes.
    Diabetes research and clinical practice, 2012, Volume: 98, Issue:1

    Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Pio

2012
[Biguanide, pioglitazone and alpha-glucosidase inhibitors].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 6

    Topics: Acidosis, Lactic; Biguanides; Body Weight; Chemical and Drug Induced Liver Injury; Digestive System;

2012
Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.
    Diabetes research and clinical practice, 2013, Volume: 99, Issue:2

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Piog

2013
Pioglitazone causing urinary bladder cancer? While waiting for the result of the debate, suggestions for physicians.
    European journal of internal medicine, 2013, Volume: 24, Issue:2

    Topics: Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Incidence; Male; Pioglitazone; Prognosis; Ri

2013
PROactive study.
    Lancet (London, England), 2006, Jan-07, Volume: 367, Issue:9504

    Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rats; Thiazolidinedio

2006
Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium.
    Toxicology and applied pharmacology, 2007, Sep-15, Volume: 223, Issue:3

    Topics: Acids; Animals; Cell Proliferation; Diet; Epidermal Growth Factor; Immunohistochemistry; Male; Perox

2007
Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells.
    The American journal of pathology, 2001, Volume: 159, Issue:2

    Topics: Aged; Blotting, Western; Cell Division; Cell Line; Chromans; Dose-Response Relationship, Drug; Human

2001